Results 171 to 180 of about 1,129 (187)

Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening

Ca-A Cancer Journal for Clinicians, 2019
Robert A Smith, Stacey A Fedewa
exaly  

Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual

Ca-A Cancer Journal for Clinicians, 2017
William M Lydiatt, Snehal G Patel, Brian O'Sullivan   +2 more
exaly  

Adolescent and young adult oncology—past, present, and future

Ca-A Cancer Journal for Clinicians, 2019
Allison G Close, Kimberly D Miller, Louis B Rapkin   +2 more
exaly  

Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening

Ca-A Cancer Journal for Clinicians, 2017
Robert A Smith, Stacey A Fedewa, Otis W Brawley   +2 more
exaly  

State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now

Ca-A Cancer Journal for Clinicians, 2016
Susan M Swetter
exaly  

New drugs. Azilsartan medoxomil, belimumab, and lurasidone hydrochloride.

Journal of the American Pharmacists Association : JAPhA, 2011
Daniel A, Hussar, Anokhi, Shah
openaire   +1 more source

The Potential Blood Pressure Lowering Benefit of Azilsartan Medoxomil

MD Conference Express, 2010
openaire   +1 more source

Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening

Ca-A Cancer Journal for Clinicians, 2016
Robert A Smith, Stacey A Fedewa, Joannie Lortet-Tieulent   +2 more
exaly  

Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer‐related cognitive impairment in adults

Ca-A Cancer Journal for Clinicians, 2015
Jeffrey S Wefel, Shelli R Kesler
exaly  

Cancer screening, prevention, and treatment in people with mental illness

Ca-A Cancer Journal for Clinicians, 2016
Ana Stefancic, Amy T Cunningham, Richard C Wender   +2 more
exaly